子宫内膜癌雌、孕激素受体和C-erbB-2检测的临床意义

目的 检测子宫内膜癌组织中雌激素受体(ER)、孕激素受体(PR)及癌基因蛋白C-erbB-2表达的阳性率并探讨其与预后的关系.方法 用免疫组织化学法对32份子宫内膜癌标本进行了ER、PR及C-erbB-2的检测.结果 子宫内膜癌组织中ER、PR、C-erbB-2的阳性率分别为53.1%、50.0%、46.9%.ER、PR的阳性表达率与癌组织的细胞分化程度有关,随着子宫内膜癌组织学分级的增高,ER、PR阳性表达率逐渐降低,C-erbB-2的阳性表达率与肿瘤病理分级呈正相关,与ER、PR表达呈负相关.结论 ER、PR、C-erbB-2均反映了子宫内膜癌的生物学行为,其测定对预测预后、指导选择内分泌治疗具有重要意义.

Expression of ER,PR,C-erbB-2 in endometrial carcinoma and their clinical significance

Objective　To assay the positive expression rate of estrogen receptor(ER), progesterone receptor(PR) and cerbB-2 in endometrial carcinoma and the prognosis behavior. Methods　ER, PR, C-erbB-2 of 32 cases of endometrial carcinoma specimen were measured by immunohistochemical method. Results　The positive expression rate of ER, PR, C-erbB-2 were 53.1 %, 50.0 %, 46.9 % respectively in endometrial carcinoma. The positive expression rate of ER, PR were related to the grades of tumor. The positive expression rate of ER, PR drop lower with grade of tumor in endometrial carcinoma rising higher(P <0.05). The expression of the C-erbB-2 was negative-correlated with that of ER and PR, and positive-correlated with the pathological grade of endometrial carcinoma. Conclusion　The levels of ER, PR and C-erbB-2 are associated with the biologic behaviors of endometrial carcinoma and the assays are important in predicting prognosis and selecting clinical endocrinotherapy.